(Q33392647)

26 July 2017

title

New parenteral anticoagulants in development (English)

1 reference

26 July 2017

1 reference

1 reference

Antonio Gómez-Outes

1

0 references

author name string

Maria Luisa Suárez-Gea

2

1 reference

26 July 2017

Ramón Lecumberri

3

1 reference

26 July 2017

Eduardo Rocha

4

1 reference

26 July 2017

Carmen Pozo-Hernández

5

1 reference

26 July 2017

Emilio Vargas-Castrillón

6

1 reference

26 July 2017

publication date

2 November 2010

1 reference

Therapeutic advances in cardiovascular disease

26 July 2017

published in

1 reference

26 July 2017

volume

5

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

33-59

1 reference

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

New oral anticoagulant drugs in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

The 'precautionary principle' as a guide for future drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Factor Xa or thrombin: is factor Xa a better target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

An overview of the structure and function of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

New anticoagulants: focus on venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

The epidemiology of venous thromboembolism in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Sulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Review of the rebound phenomenon in new anticoagulant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Aptamers as therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Triggers, targets and treatments for thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

The challenge of regulating anticoagulant drugs: focus on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Serious anaphylactic reactions due to protamine sulfate: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

RNA aptamers as reversible antagonists of coagulation factor IXa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Inhibition of factor XIa as a new approach to anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Review: anticoagulation for haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Idraparinux versus standard therapy for venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Extended prophylaxis of venous thromboembolism with idraparinux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Tolerability and pharmacokinetics of TB-402 in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710387808

21 January 2018

Identifiers

DOI

10.1177/1753944710387808

1 reference

26 July 2017

1 reference